243 related articles for article (PubMed ID: 26210752)
1. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.
Frost AE; Barst RJ; Hoeper MM; Chang HJ; Frantz RP; Fukumoto Y; Galié N; Hassoun PM; Klose H; Matsubara H; Morrell NW; Peacock AJ; Pfeifer M; Simonneau G; Tapson VF; Torres F; Dario Vizza C; Lawrence D; Yang W; Felser JM; Quinn DA; Ghofrani HA
J Heart Lung Transplant; 2015 Nov; 34(11):1366-75. PubMed ID: 26210752
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Hoeper MM; Barst RJ; Bourge RC; Feldman J; Frost AE; Galié N; Gómez-Sánchez MA; Grimminger F; Grünig E; Hassoun PM; Morrell NW; Peacock AJ; Satoh T; Simonneau G; Tapson VF; Torres F; Lawrence D; Quinn DA; Ghofrani HA
Circulation; 2013 Mar; 127(10):1128-38. PubMed ID: 23403476
[TBL] [Abstract][Full Text] [Related]
3. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.
Ghofrani HA; Morrell NW; Hoeper MM; Olschewski H; Peacock AJ; Barst RJ; Shapiro S; Golpon H; Toshner M; Grimminger F; Pascoe S
Am J Respir Crit Care Med; 2010 Nov; 182(9):1171-7. PubMed ID: 20581169
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Ogawa A; Miyaji K; Matsubara H
Respir Med; 2017 Oct; 131():215-219. PubMed ID: 28947033
[TBL] [Abstract][Full Text] [Related]
5. Beraprost therapy for pulmonary arterial hypertension.
Barst RJ; McGoon M; McLaughlin V; Tapson V; Rich S; Rubin L; Wasserman K; Oudiz R; Shapiro S; Robbins IM; Channick R; Badesch D; Rayburn BK; Flinchbaugh R; Sigman J; Arneson C; Jeffs R;
J Am Coll Cardiol; 2003 Jun; 41(12):2119-25. PubMed ID: 12821234
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension.
Speich R; Ulrich S; Domenighetti G; Huber LC; Fischler M; Treder U; Breitenstein A
Respiration; 2015; 89(6):515-24. PubMed ID: 26043786
[TBL] [Abstract][Full Text] [Related]
7. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.
Shah AM; Campbell P; Rocha GQ; Peacock A; Barst RJ; Quinn D; Solomon SD;
Eur Heart J; 2015 Mar; 36(10):623-32. PubMed ID: 24566799
[TBL] [Abstract][Full Text] [Related]
8. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ
Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530
[TBL] [Abstract][Full Text] [Related]
9. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G;
J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
12. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
Barst RJ; Beghetti M; Pulido T; Layton G; Konourina I; Zhang M; Ivy DD;
Circulation; 2014 May; 129(19):1914-23. PubMed ID: 24637559
[TBL] [Abstract][Full Text] [Related]
13. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
14. Ambrisentan therapy for pulmonary arterial hypertension.
Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
17. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
18. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
Chin KM; Badesch DB; Robbins IM; Tapson VF; Palevsky HI; Kim NH; Kawut SM; Frost A; Benton WW; Lemarie JC; Bodin F; Rubin LJ; McLaughlin V
Am Heart J; 2014 Feb; 167(2):218-225.e1. PubMed ID: 24439983
[TBL] [Abstract][Full Text] [Related]
19. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
Wirostko BM; Tressler C; Hwang LJ; Burgess G; Laties AM
BMJ; 2012 Feb; 344():e554. PubMed ID: 22354598
[TBL] [Abstract][Full Text] [Related]
20. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
